Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0153690 (
bone metastases
)
6,382
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Although the
FAM84B
gene lies within chromosome 8q24, a locus frequently altered in prostate cancer (PC), its alteration during prostate tumorigenesis has not been well studied. We report here
FAM84B
upregulation in DU145 cell-derived prostate cancer stem-like cells (PCSLCs) and DU145 cell-produced lung metastases compared to subcutaneous xenograft tumors.
FAM84B
protein was detected in
bone metastases
and primary PCs. Nanostring examination of 7 pairs of tumor adjacent normal and PC tissues revealed elevations in
FAM84B
mRNA levels in all carcinomas. Furthermore, through analysis of
FAM84B
expression using large datasets within the Gene Expression Omnibus and OncomineTM database, we demonstrate significant increases in
FAM84B
mRNA in 343 primary PCs versus 181 normal tissues, and elevations in the
FAM84B
gene copy number (GCN) in 171 primary PCs versus 61 normal tissues. While
FAM84B
was not detected at higher levels via immunohistochemistry in high grade (Gleason score/GS 8-10) tumors compared to GS6-7 PCs, analyses of
FAM84B
mRNA and GCN using datasets within the cBioPortal database demonstrated
FAM84B
upregulation in 12% (67/549) of primary PCs and 18% (73/412) of metastatic castration resistant PCs (mCRPCs), and GCN increases in 4.8% (26/546) of primary PCs and 26% (121/467) of mCRPCs, revealing an association of the aforementioned changes with CRPC development. Of note, an increase in
FAM84B
expression was observed in xenograft CRPCs produced by LNCaP cells. Furthermore,
FAM84B
upregulation and GCN increases correlate with decreases in disease free survival and overall survival. Collectively, we demonstrate a novel association of
FAM84B
with PC tumorigenesis and CRPC progression.
...
PMID:Upregulation of FAM84B during prostate cancer progression. 2818 73